chidamide + exemestane + goserelin

This is a combination regimen of three drugs used primarily in the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer, particularly in premenopausal and postmenopausal women who have progressed after prior endocrine therapy. - **Chidamide** is a selective histone deacetylase inhibitor that modulates gene expression by altering chromatin structure, leading to cell cycle arrest and apoptosis in cancer cells. - **Exemestane** is an irreversible steroidal aromatase inhibitor that suppresses estrogen production by inhibiting the aromatase enzyme, thereby reducing estrogen-driven tumor growth. - **Goserelin** is a gonadotropin-releasing hormone agonist that induces ovarian suppression by downregulating pituitary gonadotropins, effectively lowering estrogen levels in premenopausal women. The combination aims to enhance antitumor efficacy through dual hormonal blockade and epigenetic modulation. Clinical studies have shown improved progression-free survival with this regimen compared to endocrine therapy alone[1][3][4].

Brand names

Epidaza (chidamide)Aromasin (exemestane)Zoladex (goserelin)

Other names

chidamide + aromasin + zoladex